LM Advisors LLC Acquires 29,767 Shares of Pfizer Inc. $PFE

LM Advisors LLC increased its stake in Pfizer Inc. (NYSE:PFE) by 3,716.2% in the 2nd quarter, HoldingsChannel reports. The fund owned 30,568 shares of the biopharmaceutical company’s stock after acquiring an additional 29,767 shares during the period. LM Advisors LLC’s holdings in Pfizer were worth $739,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Vermillion Wealth Management Inc. lifted its stake in shares of Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 382 shares during the last quarter. Eagle Capital Management LLC boosted its holdings in shares of Pfizer by 0.3% in the 1st quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after purchasing an additional 390 shares during the period. Delta Financial Advisors LLC increased its position in shares of Pfizer by 1.6% during the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after purchasing an additional 398 shares during the last quarter. Pines Wealth Management LLC increased its position in shares of Pfizer by 4.4% during the 4th quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 400 shares during the last quarter. Finally, Mount Vernon Associates Inc. MD raised its holdings in Pfizer by 1.0% during the 1st quarter. Mount Vernon Associates Inc. MD now owns 41,919 shares of the biopharmaceutical company’s stock valued at $1,177,000 after buying an additional 400 shares during the period. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. UBS Group restated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research report on Wednesday, May 27th. Weiss Ratings cut shares of Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, August 17th. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Monday, July 6th. JPMorgan Chase & Co. lowered their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday, July 8th. Finally, HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and dropped their price target for the stock from $32.00 to $28.00 in a research note on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $28.28.

Pfizer Price Performance

Shares of PFE stock opened at $27.97 on Tuesday. The stock has a 50 day moving average price of $25.34 and a 200 day moving average price of $26.26. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $28.75. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The firm has a market capitalization of $159.41 billion, a P/E ratio of 36.80 and a beta of 0.34.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.Pfizer’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.